AKB‐9785 and AKB‐9778 are potent inhibitors of VE‐PTP that have beneficial actions in models of retinopathy, glaucoma, diabetic nephropathy, and metastasis (Goel et al, 2013; Shen et al, 2014; Carota et al, 2019; Li et al, 2020) and have a favorable safety profile in animals and adult humans (Campochiaro et al, 2015, 2016; Li et al, 2020; Siragusa et al, 2021). Here, PTPRB is linked to glaucoma.